Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis

28 Dec 2023

Abstract excerpt

BACKGROUND: Genetic and experimental studies support a causal involvement of IL-6 (interleukin-6) signaling in atheroprogression. Although trials targeting IL-6 signaling are underway, any benefits must be balanced against an impaired host immune response. Dissecting the mechanisms that mediate the effects of IL-6 signaling on atherosclerosis could offer insights about novel drug targets with more specific...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adipokines, Inflammation, and Metabolic Diseases
Share to Atherosclerosis and Cardiovascular Diseases
Share to Chemokine receptors and signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38152968
DOI: 10.1161/circulationaha.123.064974

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on AtherosclerosisPMID 38152968Read ↗

Proteogenomic integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosisSemantic proximity Read ↗

Genetically downregulated interleukin-6 signaling is associated with a favorable cardiometabolic profile: a phenome-wide association studySemantic proximity Read ↗

Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case StudySemantic proximity Read ↗

Genetically proxied IL-6 signaling inhibition, lipoprotein(a) levels, and atherosclerotic disease risk.Semantic proximity Read ↗

Dissecting the IL-6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R.Semantic proximity Read ↗

Interleukin-6 signaling effects on ischemic stroke and other cardiovascular outcomes: a Mendelian Randomization studySemantic proximity Read ↗

A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevitySemantic proximity Read ↗

Genetic study of circulating cytokines offers insight into the determinants, cascades and effects of systemic inflammationSemantic proximity Read ↗

Epigenetic mechanisms underlying variation of IL-6, a well-established inflammation biomarker and risk factor for cardiovascular disease.Semantic proximity Read ↗

IL6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic riskSemantic proximity Read ↗

Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A Mendelian Randomization StudySemantic proximity Read ↗

Leveraging genetic data to investigate the effects of interleukin-6 receptor signalling on levels of 40 circulating cytokines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.